AL002 for Alzheimer's Disease
Palo Alto (17 mi)Overseen byTBD TBD
Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Alector Inc.
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?This trial tests AL002, a drug for early Alzheimer's disease, in people who were part of an earlier study. It aims to check if AL002 is safe and effective over time.
Eligibility Criteria
This trial is for individuals with Early Alzheimer's Disease who completed the AL002-2 study, can consent to participate, and have a caregiver involved at least 10 hours weekly. Those unable to consent or discontinued from the previous study due to safety cannot join.Treatment Details
The trial is testing the long-term effects of a drug called AL002 on safety, tolerability, and effectiveness in treating Early Alzheimer's Disease. It extends prior research by continuing treatment with this drug.
3Treatment groups
Experimental Treatment
Group I: AL002 Dose 3Experimental Treatment1 Intervention
AL002 every 4 weeks
Group II: AL002 Dose 2Experimental Treatment1 Intervention
AL002 every 4 weeks
Group III: AL002 Dose 1Experimental Treatment1 Intervention
AL002 every 4 weeks
Find a clinic near you
Research locations nearbySelect from list below to view details:
Banner Alzheimer's InstitutePhoenix, AZ
Georgetown University Medical CenterWashington, United States
SFM Clinical Research, LLCBoca Raton, FL
K2 Medical Research - MaitlandMaitland, FL
More Trial Locations
Loading ...
Who is running the clinical trial?
Alector Inc.Lead Sponsor
AbbVieIndustry Sponsor